Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. uri icon

Overview

abstract

  • Diffuse alveolar hemorrhage (DAH) is a serious pulmonary complication that occurs in patients undergoing hematopoietic stem-cell transplantation (HSCT). Current management strategies are limited to corticosteroids, platelet transfusions, and mechanical ventilator support to treat acute respiratory failure. Recombinant factor VIIa (rFVIIa) is an approved agent for the treatment of bleeding in patients with hemophilia A or B and the presence of inhibitors. We report a case of DAH after allogeneic HSCT that failed standard therapy and was then successfully treated with rFVIIa.

publication date

  • December 1, 2003

Research

keywords

  • Factor VII
  • Hematopoietic Stem Cell Transplantation
  • Hemorrhage
  • Lung Diseases
  • Recombinant Proteins

Identity

Scopus Document Identifier

  • 0345732422

Digital Object Identifier (DOI)

  • 10.1016/s0012-3692(15)31709-8

PubMed ID

  • 14665531

Additional Document Info

volume

  • 124

issue

  • 6